147 related articles for article (PubMed ID: 31622736)
1. Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.
Bardou-Jacquet E; Morandeau E; Anderson GJ; Ramm GA; Ramm LE; Morcet J; Bouzille G; Dixon J; Clouston AD; Lainé F; Turlin B; Powell LW; Deugnier YM
Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1851-1857. PubMed ID: 31622736
[TBL] [Abstract][Full Text] [Related]
2. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
[TBL] [Abstract][Full Text] [Related]
3. Iron overload and HFE gene mutations in Polish patients with liver cirrhosis.
Sikorska K; Romanowski T; Stalke P; Iżycka-Świeszewska E; Bielawski KP
Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):270-5. PubMed ID: 21669570
[TBL] [Abstract][Full Text] [Related]
4. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C.
Geier A; Reugels M; Weiskirchen R; Wasmuth HE; Dietrich CG; Siewert E; Gartung C; Lorenzen J; Bosserhoff AK; Brügmann M; Gressner AM; Matern S; Lammert F
Liver Int; 2004 Aug; 24(4):285-94. PubMed ID: 15287851
[TBL] [Abstract][Full Text] [Related]
5. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease.
Valenti L; Fracanzani AL; Bugianesi E; Dongiovanni P; Galmozzi E; Vanni E; Canavesi E; Lattuada E; Roviaro G; Marchesini G; Fargion S
Gastroenterology; 2010 Mar; 138(3):905-12. PubMed ID: 19931264
[TBL] [Abstract][Full Text] [Related]
6. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C.
Smith BC; Gorve J; Guzail MA; Day CP; Daly AK; Burt AD; Bassendine MF
Hepatology; 1998 Jun; 27(6):1695-9. PubMed ID: 9620344
[TBL] [Abstract][Full Text] [Related]
7. Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.
Chin J; Powell LW; Ramm LE; Hartel GF; Olynyk JK; Ramm GA
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1459-1468.e5. PubMed ID: 32745684
[TBL] [Abstract][Full Text] [Related]
8. Hemochromatosis and alcoholic liver disease.
Fletcher LM; Powell LW
Alcohol; 2003 Jun; 30(2):131-6. PubMed ID: 12957297
[TBL] [Abstract][Full Text] [Related]
9. Differences in hepatic phenotype between hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes.
Cheng R; Barton JC; Morrison ED; Phatak PD; Krawitt EL; Gordon SC; Kowdley KV
J Clin Gastroenterol; 2009 Jul; 43(6):569-73. PubMed ID: 19359997
[TBL] [Abstract][Full Text] [Related]
10. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype.
Gehrke SG; Stremmel W; Mathes I; Riedel HD; Bents K; Kallinowski B
J Mol Med (Berl); 2003 Dec; 81(12):780-7. PubMed ID: 14557859
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma.
Fargion S; Stazi MA; Fracanzani AL; Mattioli M; Sampietro M; Tavazzi D; Bertelli C; Patriarca V; Mariani C; Fiorelli G
Blood Cells Mol Dis; 2001; 27(2):505-11. PubMed ID: 11500061
[TBL] [Abstract][Full Text] [Related]
12. Liver iron, HFE gene mutations, and hepatocellular carcinoma occurrence in patients with cirrhosis.
Nahon P; Sutton A; Rufat P; Ziol M; Thabut G; Schischmanoff PO; Vidaud D; Charnaux N; Couvert P; Ganne-Carrie N; Trinchet JC; Gattegno L; Beaugrand M
Gastroenterology; 2008 Jan; 134(1):102-10. PubMed ID: 18061182
[TBL] [Abstract][Full Text] [Related]
13. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis.
Erhardt A; Maschner-Olberg A; Mellenthin C; Kappert G; Adams O; Donner A; Willers R; Niederau C; Häussinger D
J Hepatol; 2003 Mar; 38(3):335-42. PubMed ID: 12586300
[TBL] [Abstract][Full Text] [Related]
14. Iron-overload-related disease in HFE hereditary hemochromatosis.
Allen KJ; Gurrin LC; Constantine CC; Osborne NJ; Delatycki MB; Nicoll AJ; McLaren CE; Bahlo M; Nisselle AE; Vulpe CD; Anderson GJ; Southey MC; Giles GG; English DR; Hopper JL; Olynyk JK; Powell LW; Gertig DM
N Engl J Med; 2008 Jan; 358(3):221-30. PubMed ID: 18199861
[TBL] [Abstract][Full Text] [Related]
15. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity.
Chitturi S; Weltman M; Farrell GC; McDonald D; Kench J; Liddle C; Samarasinghe D; Lin R; Abeygunasekera S; George J
Hepatology; 2002 Jul; 36(1):142-9. PubMed ID: 12085358
[TBL] [Abstract][Full Text] [Related]
16. A population-based study of the clinical expression of the hemochromatosis gene.
Olynyk JK; Cullen DJ; Aquilia S; Rossi E; Summerville L; Powell LW
N Engl J Med; 1999 Sep; 341(10):718-24. PubMed ID: 10471457
[TBL] [Abstract][Full Text] [Related]
17. Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis.
Barton JC; Barton JC; Acton RT; So J; Chan S; Adams PC
Clin Gastroenterol Hepatol; 2012 Apr; 10(4):412-6. PubMed ID: 22265917
[TBL] [Abstract][Full Text] [Related]
18. Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancy.
Atkins JL; Pilling LC; Masoli JAH; Kuo CL; Shearman JD; Adams PC; Melzer D
JAMA; 2020 Nov; 324(20):2048-2057. PubMed ID: 33231665
[TBL] [Abstract][Full Text] [Related]
19. The ancestral haplotype markers HLA -A3 and B7 do not influence the likelihood of advanced hepatic fibrosis or cirrhosis in HFE hemochromatosis.
Olynyk JK; Grainger R; Currie H; Ramm LE; Ramm GA
Sci Rep; 2023 May; 13(1):7775. PubMed ID: 37179448
[TBL] [Abstract][Full Text] [Related]
20. Penetrance, cancer incidence and survival in HFE haemochromatosis-A population-based cohort study.
Schaefer B; Pammer LM; Pfeifer B; Neururer S; Troppmair MR; Panzer M; Wagner S; Pertler E; Gieger C; Kronenberg F; Lamina C; Tilg H; Zoller H
Liver Int; 2024 Mar; 44(3):838-847. PubMed ID: 38263707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
